Why GLP-1 Drugs Work Best When Combined With Exercise and Strength Training | Research

The takeaway

While GLP-1 agonists produce greater weight loss than lifestyle changes alone, combining them with exercise and increased protein intake preserves muscle mass and prevents weight regain after stopping medication.

Weight regain after stopping
Stopping GLP-1 therapy without established exercise habits commonly leads to weight regain — exercise is essential for maintaining results long-term

What the researchers found

The review synthesizes several key findings from recent literature:

1. GLP-1 receptor agonists often surpass lifestyle interventions alone for weight loss and metabolic/cardiovascular improvements

2. Stopping GLP-1 therapy frequently leads to weight regain when lifestyle changes haven't been established

3. Exercise helps preserve muscle mass during GLP-1-mediated weight loss, which is critical because muscle loss reduces metabolic rate and functional capacity

4. Combining GLP-1 agonists with strength training and increased protein intake mitigates the muscle loss problem

5. Long-term weight maintenance is more successful when exercise is part of the treatment plan

6. Future obesity management will likely prioritize integrated pharmacotherapy + lifestyle approaches rather than medication alone

Why it matters

Millions of people are now taking GLP-1 drugs, but the conversation has largely been about the drugs themselves rather than what should accompany them. The muscle loss problem is real — studies show 30-40% of weight lost on GLP-1 drugs can be lean mass (muscle) rather than fat. Since muscle is metabolically active and essential for mobility, losing it makes long-term weight maintenance harder and can impair quality of life, especially in older adults. This review makes the case that prescribing exercise alongside GLP-1 drugs should be standard practice.

How the study worked

This is a narrative review synthesizing recent literature on the interaction between GLP-1 receptor agonist therapy and exercise/lifestyle interventions for obesity management.

What this study cannot tell us

As a narrative review, this does not present original data or systematic methodology. The specific degree of muscle preservation from exercise during GLP-1 therapy is not quantified. The optimal exercise prescription (type, frequency, intensity, duration) for maximizing GLP-1 agonist outcomes is not fully defined. Adherence to exercise programs is a well-known challenge, and the review does not address strategies for improving long-term exercise compliance. The review focuses on exercise and does not detail other lifestyle factors like sleep, stress, or behavioral therapy.

How to read the evidence

This is a narrative review synthesizing existing literature. It does not present new data or use systematic review methodology. The individual claims are supported by published studies, but the strength of evidence varies across the cited literature.

When this study was published

Published in 2025, this review addresses one of the most pressing current questions in obesity medicine as GLP-1 agonist use explodes worldwide.

The bigger picture

The GLP-1 revolution has raised a fundamental question in obesity medicine: should drugs replace lifestyle interventions or complement them? This review firmly advocates for integration. The parallel with other chronic disease management is clear — just as blood pressure treatment combines medication with diet and exercise, obesity treatment should combine pharmacotherapy with structured physical activity. As insurance coverage for GLP-1 drugs expands and costs potentially decrease, establishing exercise as a mandatory companion to drug therapy could significantly improve long-term outcomes.

Questions still open

What is the optimal exercise prescription (resistance vs. aerobic vs. combined) to maximize muscle preservation during GLP-1 agonist therapy?
How much protein intake is needed alongside GLP-1 drugs and exercise to prevent clinically significant muscle loss?
Would mandating exercise counseling with every GLP-1 prescription improve long-term weight maintenance outcomes?

Common questions

Why do people lose muscle on GLP-1 drugs, and why does it matter?

GLP-1 drugs cause significant weight loss by reducing appetite, but the body doesn't only burn fat — it also breaks down muscle for energy, especially during rapid weight loss. Studies suggest 30-40% of weight lost can be muscle rather than fat. This matters because muscle is your body's engine for burning calories, maintaining mobility, and supporting bone health. Losing too much muscle makes your metabolism slower, increasing the risk of regaining weight and reducing quality of life.

What kind of exercise should people on GLP-1 drugs do?

The review specifically highlights strength training (resistance exercise) as the most important type for preserving muscle mass during GLP-1-mediated weight loss. Combined with increased protein intake, strength training signals to the body to preserve muscle even as overall weight drops. Aerobic exercise (walking, cycling) is also valuable for cardiovascular health and calorie burning, but without resistance training, muscle loss is more likely. An ideal program would include both types.

Read the original research

GLP-1 agonists and exercise: the future of lifestyle prioritization.

Frontiers in clinical diabetes and healthcare, 6, 1720794

View on PubMed ↗Publisher’s paper ↗

Citation

Codella, Roberto; Senesi, Pamela; Luzi, Livio. (2025). GLP-1 agonists and exercise: the future of lifestyle prioritization.. Frontiers in clinical diabetes and healthcare, 6, 1720794. https://doi.org/10.3389/fcdhc.2025.1720794